Galera Therapeutics Inc. (GRTX)
OTC: GRTX
· Real-Time Price · USD
0.03
0.00 (9.09%)
At close: Apr 04, 2025, 2:24 PM
Galera Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | 88K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | 9K | 215K | 12K | 12K | n/a | 26K | 27K | 30K | 31K | 464K | 106K | 102K | 106K |
Gross Profit | n/a | n/a | -9K | -127K | -12K | -12K | n/a | -26K | -27K | -30K | -31K | -464K | -106K | -102K | -106K |
Operating Income | -5.91M | -4.21M | -4.58M | -5.18M | -13.4M | -16.81M | -13.88M | -13.16M | -12.96M | -11.96M | -13.15M | -14.5M | -20.3M | -21.09M | -17.48M |
Interest Income | 126K | 149K | 196K | 295K | 411K | 494K | 395K | 250K | 171K | 71K | 14K | 4K | 3K | 6K | 19K |
Pretax Income | -5.78M | -4.06M | -4.38M | -5.59M | -15.07M | -20.71M | -17.71M | -16.26M | -16.03M | -14.56M | -15.44M | -16.81M | -22.63M | -22.39M | -18.71M |
Net Income | -5.58M | -4.06M | -4.38M | -5.59M | -15.07M | -20.71M | -17.71M | -16.19M | -19.11M | -17.16M | -17.73M | -16.81M | -22.63M | -22.39M | -18.71M |
Selling & General & Admin | 3.44M | 2.78M | 3.08M | 1.77M | 4.99M | 9.25M | 6.61M | 5.02M | 4.85M | 5.29M | 5.05M | 5.28M | 5.49M | 5.12M | 5.06M |
Research & Development | 305K | 1.43M | 1.49M | 3.19M | 6.09M | 7.56M | 7.27M | 8.14M | 8.11M | 6.66M | 8.11M | 9.21M | 14.81M | 15.97M | 12.42M |
Other Expenses | 2.16M | n/a | n/a | 3.83M | n/a | n/a | n/a | -3.1M | n/a | n/a | n/a | -2.31M | n/a | n/a | n/a |
Operating Expenses | 5.91M | 4.21M | 4.57M | 4.96M | 11.09M | 16.81M | 13.88M | 13.16M | 12.96M | 11.96M | 13.15M | 14.5M | 20.3M | 21.09M | 17.48M |
Interest Expense | n/a | n/a | n/a | 705K | 2.09M | 4.4M | 4.22M | 3.32M | 3.25M | 2.7M | 2.3M | 2.31M | 2.33M | 1.3M | 1.25M |
Selling & Marketing Expenses | n/a | n/a | -9K | -215K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 5.91M | 4.21M | 4.58M | 5.18M | 11.09M | 16.81M | 13.88M | 13.16M | 12.96M | 11.96M | 13.15M | 14.5M | 20.3M | 21.09M | 17.48M |
Income Tax Expense | -203K | n/a | -34.28K | -10.63M | 2.09M | 494K | n/a | -70K | 3.07M | 2.6M | 2.29M | 14.38M | 2.33M | 1.3M | 19K |
Shares Outstanding (Basic) | 54.39M | 54.39M | 54.39M | 54.39M | 45.48M | 42.92M | 35.2M | 27.94M | 26.82M | 26.82M | 26.75M | 26.44M | 26.3M | 25.4M | 24.99M |
Shares Outstanding (Diluted) | 54.39M | 54.39M | 54.39M | 54.39M | 45.48M | 42.92M | 35.2M | 27.94M | 26.82M | 26.82M | 26.75M | 26.44M | 26.3M | 25.4M | 24.99M |
EPS (Basic) | -0.1 | -0.07 | -0.08 | -0.1 | -0.33 | -0.48 | -0.5 | -0.58 | -0.71 | -0.64 | -0.66 | -0.64 | -0.86 | -0.88 | -0.75 |
EPS (Diluted) | -0.1 | -0.07 | -0.08 | -0.1 | -0.33 | -0.48 | -0.5 | -0.58 | -0.71 | -0.64 | -0.66 | -0.64 | -0.86 | -0.88 | -0.75 |
EBITDA | -5.78M | -4.06M | -4.57M | -4.96M | -12.97M | -16.3M | -13.47M | -13.13M | -12.96M | -11.83M | -13.11M | -14.03M | -20.19M | -20.99M | -17.36M |
EBIT | -5.78M | -4.06M | -4.38M | -4.88M | -12.99M | -16.31M | -13.49M | -12.93M | -12.79M | -11.86M | -13.14M | -14.49M | -20.3M | -21.08M | -17.46M |
Depreciation & Amortization | 5K | 151K | 9K | 215K | 12K | 12K | 20K | 26K | 27K | 30K | 31K | 464K | 106K | 102K | 106K |